Pittsburgh, PA Clinical Trials Report — April 2026

April 2026 presents a crucial window for Pittsburgh residents considering participation in clinical research, especially for those looking to join studies before enrollment concludes. Across the city, 80 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 15 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various conditions, from sleep disorders to cancer, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Sleep (4 trials)
• Cancer (4 trials)
• Schizophrenia (3 trials)
• Chronic pain (3 trials)
• Metastatic dedifferentiated liposarcoma (2 trials)
• Primary peritoneal cancer (2 trials)
• Metastatic nut carcinoma (2 trials)
• Cardiovascular diseases (2 trials)
• Chronic pancreatitis (2 trials)
• Anatomic stage iii breast cancer ajcc v8 (2 trials)

This month, Pittsburgh welcomed 9 new clinical trials, a decrease from the 12 trials that launched in March 2026. Despite this slight dip in new openings, the city continues to be a vibrant hub for medical research, with a total of 1,187 clinical trials currently recruiting across 396 research facilities.

Spotlight on New Research Opportunities

April brings several high-profile new trials to Pittsburgh, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
• Kinaset Therapeutics Inc is launching NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This Phase 2 dose-ranging study aims for 512 participants to evaluate the efficacy and safety of Frevecitinib (KN-002) over a 12-week treatment period in patients with severe asthma not controlled with medium to high dose ICS/LABA.
• Carelon Research is initiating NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This pragmatic clinical trial, designed for 390 participants, aims to learn if the WE BEAT program, a 5-week group-based online wellbeing and skill-building program, can help teens with congenital heart disease (CHD) improve their ability to handle stress.
• Boehringer Ingelheim is sponsoring NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer, aiming for 390 participants, to find out if a study medicine called obrixtamig plus standard chemotherapy improves survival when compared to standard chemotherapy alone.

New trials this month are exploring a range of conditions, including adolescent congenital heart disease, cardiovascular disease, cerebral palsy, chronic kidney disease, and peri-implantitis. Behavioral, device, and drug trials each account for 3 of the new studies, indicating a diverse research landscape.

For individuals without a specific medical condition, there are opportunities to contribute. Of the 9 new trials launched this month, 1 is actively seeking healthy volunteers. Across Pittsburgh, a total of 122 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Pittsburgh's Leading Research Hubs

Pittsburgh is home to some of Pennsylvania's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Pittsburgh (139 trials)
• University of Pittsburgh Medical Center (138 trials)
• UPMC Hillman Cancer Center (88 trials)
• University of Pittsburgh Cancer Institute (UPCI) (85 trials)
• Allegheny General Hospital (62 trials)
• Children's Hospital of Pittsburgh of UPMC (59 trials)
• UPMC Children's Hospital of Pittsburgh (45 trials)
• UPMC-Passavant Hospital (40 trials)
• Research Site (36 trials)
• UPMC-Saint Clair Hospital Cancer Center (31 trials)
• Allegheny Health Network (30 trials)
• UPMC-Magee Womens Hospital (27 trials)

These institutions, particularly the extensive University of Pittsburgh and UPMC network, offer a broad spectrum of research, from oncology at UPMC Hillman Cancer Center and UPCI, to pediatric care at Children's Hospital of Pittsburgh of UPMC, and general medical advancements across the UPMC system and Allegheny Health Network.

Broadening Your Search: Nearby Options

While Pittsburgh offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Pennsylvania. Other cities with active trials include Philadelphia (14 trials), Cranberry Township (2 trials), Hershey (1 trial), Kingston (1 trial), Erie (1 trial), West Conshohocken (1 trial), Yardley (1 trial), and York (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched this month, 3 include children and 6 include older adults, ensuring that various age groups have opportunities to contribute to medical science. Academic institutions, notably the University of Pittsburgh, continue to play a vital role in Pittsburgh's research ecosystem, sponsoring 3 of the new trials. Industry sponsors like Boehringer Ingelheim, Kinaset Therapeutics Inc, and Incyte Corporation are also driving significant research efforts.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials and the continued exploration of new therapeutic strategies, with Pittsburgh's robust research community at the forefront of medical innovation.